Management of Perinatal Mood and Anxiety Disorders

Treatment with medication and/or specialist referral should be considered for patients who screen positive for PMADs.27 Depending on the severity of the mood disorder, a nonpharmacological approach such as psychotherapy may be taken first and can be used in combination with pharmacotherapy.33

A 2021 systematic review by Dominguez-Solis et al revealed moderate to strong evidence that nonpharmaceutical interventions could reduce anxiety in the perinatal period. They determined that cognitive behavioral therapy (CBT), massages by partners, yoga, and music therapy were most effective.34 Findings from a 2020 randomized controlled study by Zemestanti et al showed similar results. They found that mindfulness-based CBT successfully improved symptoms of depression and anxiety among 38 pregnant women.35

Medication selection should be made based on the agent’s safety profile and the patient’s symptoms, history of medication use, and preferences, according to ACOG. Clinicians who do not specialize in psychiatric management should refer patients to a psychiatrist for pharmacotherapy.33


Continue Reading

A risk-benefit analysis is needed when considering pharmacotherapy for PMADs.36-38 Benzodiazepines, which provide quick relief from anxiety and panic disorders, are associated with neonatal side effects such as preterm delivery, low birth weight, and floppy infant syndrome as well as a slightly increased incidence of cleft lip or palate (absolute risk is increased by 0.01%).33,36-38 Exposure to benzodiazepines should be avoided during the first 3 months of pregnancy, but these agents are not contraindicated in later stages of pregnancy. If necessary, a benzodiazepine with a shorter half-life may be prescribed.38

Use of selective serotonin reuptake inhibitors (SSRIs) in pregnancy has been linked to reductions in birth weight, low birth weight, and small for gestational age; however, not all studies show this association.33,36 In a literature review by Womersley et al, paroxetine and fluoxetine were associated with significant fetal malformations in utero.39 Specifically, paroxetine was linked to cardiac defects including septal defects and right ventricular outflow obstruction in the neonate, and hence should be avoided in pregnancy.36,39 Sertraline and citalopram were found to be the safest SSRIs to use in pregnancy.39 Data on the impact of MAOIs, venlafaxine, mirtazapine, and bupropion in pregnancy are limited and therefore should not be considered as first-line agents if possible.37

A number of studies have concluded that lithium, valproate, and carbamazepine should be avoided in pregnancy, particularly during the first trimester, given the increased risk for fetal malformations an abnormalites.36

Prevention of Hypertensive Disorders of Pregnancy

Evidence suggests that daily low-dose aspirin (81 mg) can help prevent preeclampsia and reduce the risk for perinatal death.40 The USPSTF recommends daily aspirin use after 12 weeks of gestation for pregnant persons who are at high risk.40 ACOG supports this strategy and recommends initiating this regimen for high-risk patients between 12 and 28 weeks of gestation, but ideally before 16 weeks of pregnancy, until delivery.41

High-risk patients are defined as pregnant individuals who have a history of preeclampsia, are carrying multiple fetuses, or have comorbidities such as chronic hypertension, type 1 or type 2 diabetes, kidney disease, or autoimmune disease as well as those who carry multiple moderate-risk factors.40 Moderate-risk factors include nulliparity, age 35 or older, obesity, lower income, in vitro conception, and personal history factors such as previous adverse pregnancy outcome.40 Non-Hispanic Black persons are at increased risk for preeclampsia because of barriers to health care resulting from environmental, social, and historical inequities.40 Contraindications to the low-dose aspirin regimen include nasal polyps, aspirin/NSAID allergy, and/or asthma with a history of aspirin-induced acute bronchospasm.41

A pill combining calcium with aspirin may be most valuable in preventing HDP, according to findings from a review conducted by Browne et al.42 The authors also evaluated the effects of vitamin D, vitamin B12, and folic acid supplementation on preventing HDP and determined the findings were inconclusive.42 Diet and lifestyle changes also have the potential to reduce the risk for preeclampsia. In a 2014 literature review, Allen et al found that dietary interventions reduced the risk for preeclampsia by 33%.43 These dietary changes varied by study but included interventions such as a diet with a high intake of vegetables, fruits, and vegetable oil; a cholesterol-lowering diet; and prescription of a balanced nutritional regimen in patients with obesity.

Patient Education

Pregnant patients should be educated on the signs and symptoms of perinatal depression and anxiety. If patients experience any of these symptoms, they should contact their ob-gyn or primary care provider (Table). To aid in this discussion, the PSI created a self-evaluation tool for patients to complete, which allows clinicians to gauge mental health concerns and risk factors.44 Providers must inform patients that they should not self-discontinue any current psychotropic medications. Untreated psychiatric illness can lead to decreased compliance with prenatal care, inadequate nutrition, exposure to other medications or herbal remedies, increased alcohol and tobacco use, deficits in mother-infant bonding, and issues within the family environment.36

Conclusion

Further research is needed to better understand the relationship between HDP and PMADs. Rates of anxiety and depression have increased during the ongoing COVID-19 pandemic. Therefore, it is essential to screen for and treat mental health conditions at prenatal visits and offer patient education on this topic. Obstetric and family practice clinicians must offer preventative interventions for preeclampsia to all high-risk patients including those who are experiencing symptoms of PMADs.

Gina Scandaglia, PA-S, is a PA student at St John’s University in Queens, New York; Corinne I. Alois, MS, PA-C, is an assistant professor in the PA program at St. John’s University; Louise Lee, EdD, MHA, PA-C, is an associate professor and director of PA studies at St. John’s University.

References

  1. Brown MA, Magee LA, Kenny LC, et al. Hypertensive disorders of pregnancy. Hypertension. 2018;72:24-43. doi:10.1161/hypertensionaha.117.10803
  2. Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):391-403. doi:10.1016/j.bpobgyn.2011.01.006
  3. Preeclampsia and eclampsia. Eunice Kennedy Shriver National Institute of Child Health and Human Development. Updated January 31, 2017. Accessed November 23, 2021. https://www.nichd.nih.gov/health/topics/preeclampsia
  4. Abu Samra K. The eye and visual system in the preeclampsia/eclampsia syndrome: what to expect? Saudi J Ophthalmol. 2013;27(1):51-53. doi:10.1016/j.sjopt.2012.04.003
  5. Leeman L, Dresang LT, Fontaine P. Hypertensive disorders of pregnancy. Am Fam Physician. 2016;93(2):121-127.
  6. Preterm birth. World Health Organization. February 19, 2018. Accessed November 23, 2021. https://www.who.int/news-room/fact-sheets/detail/preterm-birth
  7. American College of Obstetricians and Gynecologists and the Society for Maternal–Fetal Medicine, Kilpatrick SK, Ecker JL. Severe maternal morbidity: screening and review. Am J Obstet Gynecol. 2016;215(3):B17-22. doi:10.1016/j.ajog.2016.07.050.
  8. Pregnancy mortality surveillance system. Centers for Disease Control and Prevention. Updated November 25, 2020. Accessed April 7, 2022. https://www.cdc.gov/reproductivehealth/maternal-mortality/pregnancy-mortality-surveillance-system.htm#causes
  9. Data on pregnancy complications. Centers for Disease Control and Prevention. Updated February 28, 2019. Accessed April 7, 2022. https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pregnancy-complications-data.htm
  10. Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia. Circ Res. 2019;124(7):1094-1112. doi:10.1161/circresaha.118.313276
  11. Dachew BA, Scott JG, Alati R. Hypertensive disorders during pregnancy and perinatal mental health symptoms. J Affect Disord Rep. 2021;6:100245. doi:10.1016/j.jadr.2021.100245
  12. Postpartum support international perinatal mood and anxiety disorders fact sheet. Postpartum Support International (PSI). Accessed April 7, 2021. https://www.postpartum.net/wp-content/uploads/2014/11/PSI-PMD-FACT-SHEET.pdf
  13. Raina J, El-Messidi A, Badeghiesh A, Tulandi T, Nguyen T-V, Suarthana E. Pregnancy hypertension and its association with maternal anxiety and mood disorders: a population-based study of 9 million pregnancies. J Affect Disord. 2021;281:533-538. doi:10.1016/j.jad.2020.10.058
  14. Vianna P, Bauer ME, Dornfeld D, Chies JA. Distress conditions during pregnancy may lead to pre-eclampsia by increasing cortisol levels and altering lymphocyte sensitivity to glucocorticoids. Med Hypotheses. 2011;77(2):188-191. doi:10.1016/j.mehy.2011.04.007
  15. Kotlar B, Gerson E, Petrillo S, Langer A, Tiemeier H. The impact of the COVID-19 pandemic on maternal and perinatal health: a scoping review. Reprod Health. 2021;18(1):10. doi:10.1186/s12978-021-01070-6
  16. Nowacka U, Kozlowski S, Januszewski M, Sierdzinski J, Jakimiuk A, Issat T. COVID-19 pandemic-related anxiety in pregnant women. Int J Environ Res Public Health. 2021;18(14):7221. doi:10.3390/ijerph18147221
  17. Thombre MK, Talge NM, Holzman C. Association between pre-pregnancy depression/anxiety symptoms and hypertensive disorders of pregnancy. J Womens Health (Larchmt). 2015;24(3):228-236. doi:10.1089/jwh.2014.4902
  18. Shay M, MacKinnon AL, Metcalfe A, et al. Depressed mood and anxiety as risk factors for hypertensive disorders of pregnancy: a systematic review and meta-analysis. Psychol Med. 2020;50(13):2128-2140. doi:10.1017/s0033291720003062
  19. Mbarak B, Kilewo C, Kuganda S, Sunguya BF. Postpartum depression among women with pre-eclampsia and eclampsia in Tanzania; a call for integrative intervention. BMC Pregnancy Childbirth. 2019;19(1):270. doi:10.1186/s12884-019-2395-3
  20. Roberts L, Davis GK, Homer CS. Depression, anxiety, and post-traumatic stress disorder following a hypertensive disorder of pregnancy: a narrative literature review. Front Cardiovasc Med. 2019;6:147 doi:10.3389/fcvm.2019.00147
  21. Torres-Lagunas MA, Vega-Morales EG, Vinalay-Carrillo I, Cortaza-Ramírez L, Alfonso-Gutiérrez L. Factores de riesgo psicosociales asociados a preeclampsia en mujeres mexicanas: análisis comparado en tres estados. Enfermería Universitaria. 2018;15(3):226-243. doi:10.22201/eneo.23958421e.2018.3.65987
  22. Ajah LO, Ozonu NC, Ezeonu PO, Lawani LO, Obuna JA, Onwe EO. The feto-maternal outcome of preeclampsia with severe features and eclampsia in Abakaliki, south-east Nigeria. J Clin Diagn Res. 2016;10(9):QC18-QC21. doi:10.7860/jcdr/2016/21078.8499
  23. Roy-Matton N, Moutquin J-M, Brown C, Carrier N, Bell L. The impact of perceived maternal stress and other psychosocial risk factors on pregnancy complications. J Obstet Gynaecol Can. 2011;33(4):344-352. doi:10.1016/s1701-2163(16)34852-6
  24. Giurgescu C, Sanguanklin N, Engeland CG, et al. Relationships among psychosocial factors, biomarkers, preeclampsia, and preterm birth in African American women: a pilot. Appl Nurs Res. 2015;28(1):e1-6. doi:10.1016/j.apnr.2014.09.002
  25. Hryhorczuk C, Sharma S, Fulton SE. Metabolic disturbances connecting obesity and depression. Front Neurosci. 2013;7:177. doi:10.3389/fnins.2013.00177
  26. Balhara YPS. Diabetes and psychiatric disorders. Indian J Endocrinol Metab. 2011;15(4):274-283. doi:10.4103/2230-8210.85579
  27. Screening for perinatal depression. American College of Obstetricians and Gynecologists (ACOG). Accessed April 8, 2022. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2018/11/screening-for-perinatal-depression
  28. Siu AL; US Preventive Services Task Force (USPSTF). Screening for depression in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(4):380-387. doi:10.1001/jama.2015.18392
  29. Maternal mental health: depression and anxiety: AIM program (previously Council on Patient Safety). Council on Patient Safety in Women’s Health Care. Accessed April 8, 2022. https://safehealthcareforeverywoman.org/council/patient-safety-bundles/maternal-safety-bundles/maternal-mental-health-depression-and-anxiety/
  30. Screening recommendations. Postpartum Support International (PSI). Published December 11, 2020. Accessed April 8, 2022. https://www.postpartum.net/professionals/screening/
  31. Matthey S, Fisher J, Rowe H. Using the Edinburgh postnatal depression scale to screen for anxiety disorders: conceptual and methodological considerations. J Affect Disord. 2013;146(2):224-230. doi:10.1016/j.jad.2012.09.009
  32. Simpson W, Glazer M, Michalski N, Steiner M, Frey BN. Comparative efficacy of the Generalized Anxiety Disorder 7-item scale and the Edinburgh postnatal depression scale as screening tools for generalized anxiety disorder in pregnancy and the postpartum period. Can J Psychiatry. 2014;59(8):434-440. doi:10.1177/070674371405900806
  33. ACOG Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008;111(4):1001-1020. doi:10.1097/AOG.0b013e31816fd910
  34. Domínguez-Solís E, Lima-Serrano M, Lima-Rodríguez JS. Non-pharmacological interventions to reduce anxiety in pregnancy, labor and postpartum: a systematic review. Midwifery. 2021;102:103126. doi:10.1016/j.midw.2021.103126
  35. Zemestani M, Fazeli Nikoo Z. Effectiveness of mindfulness-based cognitive therapy for comorbid depression and anxiety in pregnancy: a randomized controlled trial. Arch Womens Ment Health. 2019;23(2):207-214. doi:10.1007/s00737-019-00962-8
  36. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No. 92. Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008;111(4):1001-1020. doi:10.1097/aog.0b013e31816fd910
  37. Ram D, Gandotra S. Antidepressants, anxiolytics, and hypnotics in pregnancy and lactation. Indian J Psychiatry. 2015;57(Suppl 2):S354-S371. doi:10.4103/0019-5545.161504
  38. Shyken JM, Babbar S, Babbar S, Forinash A. Benzodiazepines in pregnancy. Clin Obstet Gynecol. 2019;62(1):156-167. doi:10.1097/grf.0000000000000417
  39. Womersley K, Ripullone K, Agius M. What are the risks associated with different selective serotonin re-uptake inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence. Psychiatr Danub. 2017;29(Suppl 3):629-644.
  40. US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, et al. Aspirin use to prevent preeclampsia and related morbidity and mortality: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(12):1186-1191. doi:10.1001/jama.2021.14781
  41. ACOG Committee Opinion No. 743: low-dose aspirin use during pregnancy. Obstet Gynecol. 2018;132(1):e44-e52. doi:10.1097/AOG.0000000000002708
  42. Browne JL, Klipstein-Grobusch K, Franx A, Grobbee DE. Prevention of hypertensive disorders of pregnancy: a novel application of the polypill concept. Curr Cardiol Rep. 2016;18(6):59. doi:10.1007/s11886-016-0725-x
  43. Allen R, Rogozinska E, Sivarajasingam P, Khan KS, Thangaratinam S. Effect of diet- and lifestyle-based metabolic risk-modifying interventions on preeclampsia: a meta-analysis. Acta Obstet Gynecol Scand. 2014;93(10):973-985. doi:10.1111/aogs.12467
  44. Perinatal mental health discussion tool. Postpartum Support International (PSI). Accessed April 8, 2022. https://www.postpartum.net/resources/discussion-tool/

This article originally appeared on Clinical Advisor